A RANDOMIZED PHASE II STUDY ON BEVACIZUMAB VERSUS BEVACIZUMAB PLUS LOMUSTINE VERSUS LOMUSTINE SINGLE AGENTIN RECURRENT GLIOBLA STOMA: THE DUTCH BELOB STUDY

被引：0

作者：

Taal, Walter ^{[1
]}

Oosterkamp, H. ^{[2
]}

Walenkamp, Annemieke ^{[3
]}

Beerenpoot, Lucas ^{[4
]}

Hanse, Monique ^{[5
]}

Buter, Jan ^{[6
]}

Honkoop, Aafke ^{[7
]}

Boerman, Dolf ^{[8
]}

de Vos, Filip ^{[9
]}

Jansen, R. ^{[10
]}

van der Berkmortel, Franchette ^{[11
]}

Brandsma, Dieta ^{[12
]}

Enting, Roelien ^{[3
]}

Kros, Johan ^{[1
]}

Bromberg, Jacoline ^{[1
]}

van Heuvel, Irene ^{[1
]}

Smits, Marion ^{[1
]}

van der Holt, Ronnie ^{[1
]}

Vernhout, Rene ^{[1
]}

van den Bent, Martin ^{[1
]}

机构：

[1] ErasmusMC, Rotterdam, Netherlands

[2] MCHaaglanden, The Hague, Netherlands

[3] Univ Med Ctr Groningen, Groningen, Netherlands

[4] St Elizabeth Hosp, Tilburg, Netherlands

[5] Catharina Hosp, Eindhoven, Netherlands

[6] Vrije Univ Amsterdam Med Ctr, Amsterdam, Netherlands

[7] Isala Klin, Zwolle, Netherlands

[8] Rijnstate Hosp, Arnhem, Netherlands

[9] UMCU, Utrecht, Netherlands

[10] MUCM, Maastricht, Netherlands

[11] Atrium Hosp, Heerlen, Netherlands

[12] Dutch Canc Inst, Amsterdam, Netherlands

来源：

NEURO-ONCOLOGY | 2013年 / 15卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：83 / 84

页数：2

共 50 条

[1] A randomized phase II study of bevacizumab versus bevacizumab plus lomustine versus lomustine single agent in recurrent glioblastoma: The Dutch BELOB study
Taal, Walter
Oosterkamp, Hendrika M.
Walenkamp, Annemiek M. E.
Beerepoot, Laurens Victor
Hanse, Monique
Buter, J.
Honkoop, Aafke
Boerman, Dolf
De Vos, Filip Yves Francine Leon
Jansen, Rob L.
van den Berkmortel, Franchette W. P. J.
Brandsma, Dieta
Kros, Johan M.
Bromberg, Jacoline E.
van Heuvel, Irene
Smits, Marion
van der Holt, Bronno
Vernhout, Rene
Van den Bent, Martin J.
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
[2] A RANDOMIZED PHASE II STUDY ON BEVACIZUMAB VERSUS BEVACIZUMAB PLUS LOMUSTINE VERSUS LOMUSTINE: PRELIMINARY RESULTS OF THE DUTCH BELOB STUDY
Taal, Walter
Walenkamp, Annemiek M.
Taphoorn, Martin J.
Beerepoot, Laurens
Hanse, Monique
Buter, Jan
Honkoop, Aafke
Groenewegen, Gerard
Boerman, Dolf
Jansen, Rob L.
van den Berkmortel, Franchette W.
Brandsma, Dieta
Kros, Johan M.
Bromberg, Jacoline E.
van Heuvel, Irene
Smits, Marion
van der Holt, B.
Vernhout, Rene
van den Bent, Martin
[J]. NEURO-ONCOLOGY, 2012, 14 : 57 - 58
[3] FINAL ANALYSIS OF THE BELOB TRIAL (A RANDOMIZED PHASE II STUDY ON BEVACIZUMAB VERSUS BEVACIZUMAB PLUS LOMUSTINE VERSUS LOMUSTINE SINGLE AGENT IN RECURRENT GLIOBLASTOMA) AND FIRST RADIOLOGY REVIEW RESULTS
Taal, Walter
Enting, Roelien
Taphoorn, Martin
Smits, Marion
Dubbink, Hendrikus
Beerepoot, Laurens
Hanse, Monique
Bralten, Linda
Oosterkamp, Hendrika
Walenkamp, Annemiek
Buter, Jan
Honkoop, Aafke
Boerman, Dolf
de Vos, Filip
Bromberg, Jacoline
Vernhout, Rene
van der Holt, Bronno
van den Bent, Martin
[J]. NEURO-ONCOLOGY, 2014, 16
[4] FINAL ANALYSIS OF THE BELOB TRIAL (A RANDOMIZED PHASE II STUDY ON BEVACIZUMAB VERSUS BEVACIZUMAB PLUS LOMUSTINE VERSUS LOMUSTINE SINGLE AGENT IN RECURRENT GLIOBLASTOMA) AND FIRST RADIOLOGY REVIEW RESULTS
Taal, W.
Oosterkamp, H. M.
Walenkamp, A. M. E.
Dubbink, H. J.
Beerepoot, L. V.
Hanse, M.
Buter, J.
Honkoop, A.
Boerman, D.
Vos, F. Y. F.
Dinjens, W. N. M.
Enting, R. H.
Taphoorn, M. J. B.
van den Berkmortel, F. W. P. J.
Jansen, R.
Brandsma, D.
Bromberg, J. E.
van Heuvel, I.
Vernhout, R. M.
van der Holt, B.
van den Bent, M. J.
[J]. NEURO-ONCOLOGY, 2014, 16
[5] Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial
Taal, Walter
Oosterkamp, Hendrika M.
Walenkamp, Annemiek M. E.
Dubbink, Hendrikus J.
Beerepoot, Laurens V.
Hanse, Monique C. J.
Buter, Jan
Honkoop, Aafke H.
Boerman, Dolf
de Vos, Filip Y. F.
Dinjens, Winand N. M.
Enting, Roelien H.
Taphoorn, Martin J. B.
van den Berkmortel, Franchette W. P. J.
Jansen, Rob L. H.
Brandsma, Dieta
Bromberg, Jacoline E. C.
van Heuvel, Irene
Vernhout, Rene M.
van der Holt, Bronno
van den Bent, Martin J.
[J]. LANCET ONCOLOGY, 2014, 15 (09): : 943 - 953
[6] A randomized phase II trial of standard dose bevacizumab versus low dose bevacizumab plus lomustine (CCNU) in adults with recurrent glioblastoma
Weathers, Shiao-Pei
Han, Xiaosi
Liu, Diane D.
Conrad, Charles A.
Gilbert, Mark R.
Loghin, Monica E.
O'Brien, Barbara J.
Penas-Prado, Marta
Puduvalli, Vinay K.
Tremont-Lukats, Ivo
Colen, Rivka R.
Yung, W. K. Alfred
de Groot, John F.
[J]. JOURNAL OF NEURO-ONCOLOGY, 2016, 129 (03) : 487 - 494
[7] A randomized phase II trial of standard dose bevacizumab versus low dose bevacizumab plus lomustine (CCNU) in adults with recurrent glioblastoma
Shiao-Pei Weathers
Xiaosi Han
Diane D. Liu
Charles A. Conrad
Mark R. Gilbert
Monica E. Loghin
Barbara J. O’Brien
Marta Penas-Prado
Vinay K. Puduvalli
Ivo Tremont-Lukats
Rivka R. Colen
W. K. Alfred Yung
John F. de Groot
[J]. Journal of Neuro-Oncology, 2016, 129 : 487 - 494
[8] A randomized phase II trial of standard dose bevacizumab versus low dose bevacizumab plus lomustine (CCNU) in adults with recurrent glioblastoma
Weathers, Shiao-Pei S.
Han, Stan Xiaosi
Liu, Diane D.
Conrad, Charles A.
Gilbert, Mark R.
Loghin, Monica Elena
O'Brien, Barbara Jane
Penas-Prado, Marta
Puduvalli, Vinay K.
Tremont-Lukats, Ivo
Yung, W. K. Alfred
De Groot, John Frederick
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
[9] Second-line treatment of bevacizumab plus lomustine versus bevacizumab plus irinotecan in patients with recurrent glioblastoma
Simoes, J.
Tavares, N. T.
Borges, C.
Meireles, S.
Fernandes, C.
Costa, A.
Caeiro, C.
Damasceno, M.
[J]. ANNALS OF ONCOLOGY, 2018, 29
[10] Prognostic value and kinetics of circulating endothelial cells in patients with recurrent glioblastoma randomised to bevacizumab plus lomustine, bevacizumab single agent or lomustine single agent. A report from the Dutch Neuro-Oncology Group BELOB trial
N Beije
J Kraan
W Taal
B van der Holt
H M Oosterkamp
A M Walenkamp
L Beerepoot
M Hanse
M E van Linde
A Otten
R M Vernhout
F Y F de Vos
J W Gratama
S Sleijfer
M J van den Bent
[J]. British Journal of Cancer, 2015, 113 : 226 - 231

← 1 2 3 4 5 →